INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

MEETING MINUTES

Meeting Date:	**Thursday, June 12, 2025**
Time:	9:00 am Central Time
Location:	Zoom Teleconference
Institution:	University of Oklahoma, Health Sciences Center, Oklahoma City, OK
Principal Investigator:	**Adam Asch, MD**
Protocol:	Poseida Therapeutics, Inc., **P-BCMA-ALLO1-001**
NCT Number:	NCT04960579
Meeting Type:	Continuing Review of Protocol and Site
Title:	Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple Myeloma (MM)

1. Call to order:

The Meeting was called to order at 9:18 am Central Time.

2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

3. Declaration of quorum:

Five voting members were present, including two local members unaffiliated with the institution and the Institution's Biosafety Officer. Also present was one Institutional Representative and IBC Services staff. The Chair declared that a quorum was present.

4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

5. Public posting:

The Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

6. Approval of previous meeting minutes:

Minutes Approved - YES: 5 NO: 0 ABSTAIN: 0

7. Review of proposed research:

The Chair provided an overview of the protocol and status of the study.

The Chair provided an overview of changes since the last review.

8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-2 containment facilities and practices** are required for PBCMA-ALLO1, since it consists of primary human cells modified using a plasmid and mRNA. The Committee reaffirmed this determination.

The Committee previously determined that IBC oversight will continue for **3 months after the last subject's last dose of P-BCMA-ALLO1 locally**, provided all other criteria for study closure are met. The Committee reaffirmed this determination.

9. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 5 NO: 0 ABSTAIN: 0

10. Review of proposed facilities and practices:

The Chair provided an overview of the arrangement for the facilities and practices.

Points of Discussion:

1. The Committee recommended that nitrile or latex gloves be worn underneath cryogloves that are used when removing the study agent from the cryoport/liquid nitrogen tank.
2. The Committee recommended that a biohazard symbol be added to the biohazardous waste container in the [redacted] biohazardous waste storage area.
3. The Committee noted that there are 26 dosing rooms highlighted on the [redacted] map but that site documents reference rooms 1-25. The Committee recommended that the Institution follow up with IBC Services to confirm the number of rooms used and that all site documents be revised accordingly.
4. The Institutional Representative could not confirm whether study staff members had received training on the location of the nearest plumbed eyewash station in relation to the dosing rooms as previously recommended by the Committee. The Committee recommended that the Institution follow up with IBC Services to confirm that training has been provided.

11. Site requirements:

The Chair reviewed training and communication requirements for maintaining IBC approval with the Institutional Representative.

12. Vote on the Site:

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 5 NO: 0 ABSTAIN: 0

13. Advice to the Institution: None.

14. Meeting adjourned: The meeting was adjourned at 9:25 am Central Time.